Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of “Moderate Buy” from Brokerages

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has been given a consensus recommendation of “Moderate Buy” by the six brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $30.00.

Several equities analysts have commented on the company. Wall Street Zen cut Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Kyverna Therapeutics in a report on Wednesday. JPMorgan Chase & Co. cut their price target on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Friday, March 27th.

Hedge Funds Weigh In On Kyverna Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its holdings in Kyverna Therapeutics by 94.1% in the 1st quarter. Bank of America Corp DE now owns 55,728 shares of the company’s stock valued at $481,000 after acquiring an additional 27,019 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Kyverna Therapeutics by 106.6% in the 1st quarter. Renaissance Technologies LLC now owns 367,492 shares of the company’s stock valued at $3,171,000 after acquiring an additional 189,593 shares in the last quarter. Walleye Capital LLC acquired a new position in Kyverna Therapeutics in the 1st quarter valued at approximately $330,000. AIGH Capital Management LLC raised its holdings in Kyverna Therapeutics by 33.3% in the 1st quarter. AIGH Capital Management LLC now owns 2,000,000 shares of the company’s stock valued at $17,260,000 after acquiring an additional 500,000 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in Kyverna Therapeutics in the 1st quarter valued at approximately $991,000. Institutional investors and hedge funds own 18.08% of the company’s stock.

Kyverna Therapeutics Price Performance

NASDAQ KYTX opened at $7.47 on Friday. Kyverna Therapeutics has a twelve month low of $2.52 and a twelve month high of $13.67. The company has a debt-to-equity ratio of 0.13, a quick ratio of 8.15 and a current ratio of 8.15. The stock has a market capitalization of $454.10 million, a PE ratio of -2.28 and a beta of 1.95. The stock has a 50-day simple moving average of $9.02 and a 200 day simple moving average of $8.53.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.09. Research analysts anticipate that Kyverna Therapeutics will post -2.78 EPS for the current year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.